Neoadjuvant Chemohormonal Therapy Aids Locally Advanced Prostate Cancer
By Elana Gotkine HealthDay Reporter
THURSDAY, May 2, 2024 -- For patients with locally advanced prostate cancer, neoadjuvant chemohormonal therapy (NCHT) is beneficial for biochemical progression-free survival (bPFS), according to a study published online May 1 in The Journal of Urology.
Hongyang Qian, from Shanghai Jiao Tong University, and colleagues conducted a randomized trial recruiting 141 patients with locally advanced, high-risk prostate cancer who were randomly assigned to the NCHT group (who received docetaxel plus androgen deprivation therapy for six cycles) or the neoadjuvant hormone therapy (NHT) group (who received androgen deprivation therapy for 24 weeks) in a 2:1 ratio. Three-year bPFS was examined as the primary end point.
The researchers identified significant benefits in three-year bPFS for the NCHT group versus the NHT group (29 versus 9.5 percent). The NCHT group achieved a significantly longer median bPFS time than the NHT group at a median follow-up of 53 months (17 versus 14 months). In terms of pathological downstaging and minimal residual disease rates, there were no significant differences observed between the groups.
"Our clinical trial is the first to show a longer time to biochemical recurrence with chemotherapy plus standard hormone therapy for patients with locally advanced, high-risk prostate cancer," coauthor Jiahua Pan, M.D., also of Shanghai Jiao Tong University, said in a statement. "The findings add new evidence to support the use of combined chemohormonal therapy for a group of patients at high risk of recurrent, progressive prostate cancer."
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted May 2024
Read this next
Plant-Based Diet May Aid Prostate Cancer Outcomes
FRIDAY, May 3, 2024 -- Consuming a primarily plant-based diet may be associated with better cancer-specific health outcomes among men with prostate cancer, according to a study...
New Prostate Cancer Urine Test Has High Diagnostic Accuracy
MONDAY, April 22, 2024 -- A new prostate cancer test has higher diagnostic accuracy for high-grade disease than current guideline-endorsed biomarkers, according to a study...
HYPORT Noninferior for GU, GI Toxicity in Prostate Cancer
WEDNESDAY, April 10, 2024 -- For patients with prostate cancer, hypofractionated postprostatectomy radiotherapy (HYPORT) is noninferior to conventionally fractionated...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.